EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy

Christopher Hartley iD, Trung Van iD, Wikrom Karnsakul iD

Pathogens · 2024

DOI: 10.3390/pathogens13060508 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, 2024. Verfasst von Christopher Hartley und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD 21287, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Infectious Disease Transmission, Vertical, Hepatitis C, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prior to the Food and Drug Administration approval of ledipaspavir/sofosbuvir (Harvoni®) in 2014, the treatment of hepatitis C was interferon plus or minus ribavirin. This treatment had low cure rates for hepatitis C virus and was teratogenic and therefore avoided in pregnant patients. Vertical transmission is the most common transmission of hepatitis C in pediatric patients, whereas medical equipment that was not properly cleaned and sterilized, blood products which were not checked (historically), sharing and reusing syringes and needles, and dialysis are the most common forms of hepatitis C transmission in adults. The treatment of pregnant women with direct-acting antivirals is important because the treatment of pediatric patients cannot begin until three years of age and does not always occur prior to the symptom development of hepatitis C. This review article will include glecaprevir/pibrentasvir (Mayvret®), sofosbuvir/velpatasvir (Epclusa®), and sofosbuvir/velpatasvir plus voxilaprevir (Vosevi®). We aim to review the teratogenic risk of direct-acting antivirals as well as currently published clinical trials and ongoing research on direct-acting antiviral hepatitis C treatment in pregnancy in this publication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsInfectious Disease Transmission, VerticalHepatitis CPregnancy Complications, InfectiousHumansPregnancyFemaleCarbamatesHepacivirusBenzimidazolesSulfonamidesHeterocyclic Compounds, 4 or More RingsPyrrolidinesSofosbuvirDrug CombinationsLeucineQuinoxalinesLactams, MacrocyclicProline

Stichwörter der Autor:innen

direct-acting-antiviral agentshepatitis Cpregnancy

Substanzen

Antiviral AgentsCarbamatesBenzimidazolesSulfonamidesHeterocyclic Compounds, 4 or More RingsPyrrolidinesSofosbuvirDrug CombinationsLeucineQuinoxalines

Autor:innen und Institutionen

  • The Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD 21287, USA.
  • Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA.
  • Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

ORCID-Profile: Christopher Hartley, Trung Van, Wikrom Karnsakul

Zitieren

APA

Hartley, C., Van, T., & Karnsakul, W. (2024). Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy. Pathogens. https://doi.org/10.3390/pathogens13060508

Vancouver

Hartley C, Van T, Karnsakul W. Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy. Pathogens. 2024. doi:10.3390/pathogens13060508

BibTeX
@article{Hartley2024,
  author = {Hartley, Christopher and Van, Trung and Karnsakul, Wikrom},
  title = {Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy},
  journal = {Pathogens},
  year = {2024},
  doi = {10.3390/pathogens13060508}
}
Kostenlos starten →